Previous 10 | Next 10 |
- Meeting adjourned to October 10, 2022 at 11 a.m. PST - GTB encourages all stockholders of record on August 8, 2022 who have not yet voted - to do so by 11:59 p.m. PST Time on October 9, 2022 BRISBANE, CALIFORNIA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the ȁ...
GTB-5550 generates a robust and NK cell specific proliferation signal compared to IL-15 alone GTB-5550 specifically targets B7-H3+ cells GTB-5550 effectively induced NK cell degranulation and interferon gamma production in response to various prostate, brain tumor (atypical rhabdo...
BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® platform, today announced that...
GTB-3650’s IND application with the FDA expected by end of first quarter of 2023 BRISBANE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on dev...
GT Biopharma press release ( NASDAQ: GTBP ): Q2 GAAP EPS of -$0.10 beats by $0.07 . The Company had total cash, cash equivalents and short-term investments of $23.7 million as of June 30, 2022, compared to $32.0 million as of December 31, 2021. This is expected to prov...
Presented preclinical data demonstration second-generation CD19 targeting Tri-specific Killer Engager (TRIKE ® ) driving robust NK cell function against B cell malignancies at EHA 2022 Congress. GTB-5550 (B7-H3) abstract poster presentation accepted at upcoming ESMO 2022 Cong...
A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...
Ongoing experiments will evaluate the functionality and efficacy of GTB-7550 in vivo Future studies will also involve assessments of GTB-7550 TriKE efficacy in other hematologic cancers BRISBANE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (“the...
GT Biopharma press release (NASDAQ:GTBP): Q1 GAAP EPS of -$0.17. The Company had total cash, cash equivalents and short-term investments of $26.7M as of Mar. 31. Shares were trading +1.04% pre-market. For further details see: GT Biopharma GAAP EPS of -$0.17
Presented pre-clinical data at American Association for Cancer Research (AACR 2022), demonstrating GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE ® ) driving NK cell activation and ADCC against head and neck squamous cell carcinomas GT Biopharma to partici...
News, Short Squeeze, Breakout and More Instantly...
BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company’s common stock at a purcha...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 16.4% to $0.199 on volume of 720,586,242 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 74.8% to $1.8 on volume of 682,362,254 shares Pineapple Energy Inc. (PEGY) rose 80.3% to $0.1...
2024-05-20 10:43:46 ET GT Biopharma Inc (NASDAQ: GTBP) is up a whopping 150% at writing even though there hasn’t been any news to catalyse that sort of a rally in shares of the clinical-stage biopharmaceutical company. GT Biopharma stock trading volume today $GTBP did not...